Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2021-07-08 Capital/Financing Update
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - IMU 5 pages 28.2KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a proposed issue of securities by IMUGENE LIMITED. It details the number of securities to be issued, the issue price, the proposed issue date, and compliance with ASX listing rules. There is no financial performance data, management discussion, or audit information. The document is focused on capital raising activities and changes in the company's capital structure. It is not a full report but an announcement of a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2021-07-08 English
Appendix 2A 19 pages 359.6KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 2A Application for quotation of +securities' and is an official form used to apply for the quotation of securities on the ASX (Australian Securities Exchange). It includes detailed questions about the entity, the securities to be quoted, dates of issue, and references to previous announcements such as Appendix 3B. The document is a regulatory form related to capital market activities, specifically the listing or quotation of securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or a certification. The document is a formal regulatory filing announcing or applying for the quotation of securities, which fits the category of Capital/Financing Update (CAP). The length (15,000 characters) and detailed content confirm it is not a brief announcement but a substantive filing related to capital changes.
2021-07-08 English
Application for quotation of securities - IMU 8 pages 31.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and pricing. This is a formal announcement related to changes in the company's capital structure due to securities being issued or converted. It is not a financial report, earnings release, or management discussion, but rather an update on capital changes. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive filing about capital changes.
2021-07-08 English
Notice Under Section 708A 1 page 159.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 09 July 2021, providing a notice under section 708A(5) of the Corporations Act 2001. It details the issuance of ordinary shares (25,183,871 shares at $0.0155 each) related to the Vaxinia acquisition. The notice confirms compliance with relevant sections of the Corporations Act and states no excluded information is present. The content is a formal regulatory disclosure about a share issuance event, specifically a notice under a legal provision related to share issuance without disclosure. It does not contain financial statements, management discussion, or detailed report data. The document length is short (1413 characters), and it is clearly an announcement of a capital/financing event (share issuance). Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-07-08 English
Imugene Presents HER-Vaxx Update at ESMO World GI Congress 3 pages 174.7KB
Investor Presentation Classification · 95% confidence The document is an ASX announcement from Imugene Limited about a presentation at the ESMO World Congress on Gastrointestinal Cancer 2021 Annual Meeting. It details clinical trial results and data updates related to their HER-Vaxx cancer immunotherapy program. The content focuses on presenting clinical and scientific data at a conference rather than financial results or regulatory filings. There is no indication that this is a full financial report, audit report, or earnings release. It is also not a report publication announcement or a certification. The document is a presentation announcement related to clinical and scientific progress, which fits best under Investor Presentation (IP) as it provides detailed information for investors about the company's product pipeline and clinical data. The document length (5581 characters) and detailed content support this classification with high confidence.
2021-07-04 English
Change of Director's Interest Notice - LR 3 pages 255.3KB
Director's Dealing Classification · 100% confidence The document is an ASX announcement dated 05 July 2021 regarding a Non-Executive Director, Dr Lesley Russell, increasing her shareholding following the exercise of options. It includes an Appendix 3Y Change of Director's Interest Notice, which is a regulatory form used to disclose changes in directors' shareholdings. The content focuses on the director's personal share transactions and changes in securities held. There are no financial statements, earnings data, or management discussion. The document is a formal notification of a director's dealing in shares, consistent with insider trading disclosures. Therefore, the appropriate classification is Director's Dealing (DIRS). The document length and detail support this classification with high confidence.
2021-07-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.